Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07261904

BIOCHROMADERM® PMCF STUDY

The goal of this observational study is to:

* To confirm the continued performance of BIOCHROMADERM® in restoring a near-normal pigmentary appearance of the nipple-areola complex at 3 months post-pigmentation; * To confirm the continued safety of BIOCHROMADERM®, * To confirm adequate usability and describe the optimal process for BIOCHROMADERM® implantation * To assess the long-term performance of BIOCHROMADERM® in restoring a near-normal pigmentary appearance of the nipple-areola complex at 12 months post-pigmentation (Likert scale) * To assess the evolution of performance (Likert scale) between baseline, 3 months and 12 months post-pigmentation * To assess fading (pigment retention potential) over 12 months * To assess the number of pigmentation adjustments needed per patient throughout the study duration * To assess patient's satisfaction/self-confidence evolution post-treatment, both in terms of general breast appearance and as to the specific dermo-pigmentation stage * To assess the correlation of the esthetic satisfaction/self-confidence questionnaire outcomes with those of the Likert Scale and patient satisfaction VAS at 3 months and 12 months post-pigmentation

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Oscar Lambret, Lille, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female or male ≥18 years old,
  • Requiring the reconstruction of the nipple-areola complex following mastectomy,
  • Affiliated or beneficiary of a social security scheme,
  • Able and willing to provide written informed consent to study participation.

Exclusion criteria

  • Known allergy to pigment ingredients
  • Active, recent or prior history of skin disease, chronic skin disease, history of hypertrophic scars, skin infection or skin inflammatory disease,
  • Patients carrying a prosthesis (especially cardiac),
  • Patients presenting with a coagulation disorder,
  • Patients scheduled for an MRI within 6 months following pigmentation,
  • Patients scheduled for a skin esthetic treatment close to the pigmentation zone (laser, peeling, abrasion, ...) shortly after pigmentation,
  • Existing medical condition or organ pathology close to the skin that the Investigator considers may put the patient at risk or compromise their participation in the study,
  • Pregnant or breastfeeding female,
  • Currently participating to another clinical trial or having participated to a prior clinical trial within 1 month prior to inclusion into the present one,
  • Personal strong objection to medical tattooing,
  • Psychiatric illness/social situations that would limit ability to consent and/or to compliance with study requirements,
  • Under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.

Note: The recent use of permanent wrinkle or lip filling products close to the scheduled pigmentation zone (silicon, PTFE, ...) is a contraindication in the approved product IFU but is not relevant to the breast reconstruction indication.

Treatment and study plan

Primary outcomes

  1. To confirm the continued performance of BIOCHROMADERM® in restoring a near-normal pigmentary appearance of the nipple-areola complex at 3 months post-pigmentation

    Time frame: 3 months post-pigmentation

Secondary outcomes

  1. To confirm the continued safety of BIOCHROMADERM®

    Time frame: 12 months

  2. To confirm adequate usability and describe the optimal process for BIOCHROMADERM® implantation

    Time frame: 12 months

  3. To assess the long-term performance of BIOCHROMADERM® in restoring a near-normal pigmentary appearance of the nipple-areola complex at 12 months post-pigmentation (Likert scale)

    Time frame: 12 months

  4. To assess the evolution of performance (Likert scale) between baseline, 3 months and 12 months post-pigmentation

    Time frame: 12 months

  5. To assess fading (pigment retention potential) over 12 months

    Time frame: 12 months

  6. To assess the number of pigmentation adjustments needed per patient throughout the study duration

    Time frame: 12 months

  7. To assess patient's satisfaction/self-confidence evolution post-treatment, both in terms of general breast appearance and as to the specific dermo-pigmentation stage

    Time frame: 12 months

  8. To assess the correlation of the esthetic satisfaction/self-confidence questionnaire outcomes with those of the Likert Scale and patient satisfaction VAS at 3 months and 12 months post-pigmentation

    Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Marie-Hélène BACHELEY

CONTACT

[email protected]

+33785453676

Sponsors and collaborators

Lead sponsor

Laboratoires BIOTIC Phocea

Industry

Collaborators

  • Clinical Research Consultants, Inc.

Registry information

Official study title

Prospective, Observational, Multicentre, Single Group, Open-label Study to Confirm the Safety and Effectiveness of BIOCHROMADERM® Ink for the Reconstruction of the Nipple-areola Complex in Patients Undergoing Breast Reconstructive Surgery Following Mastectomy

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Dec 3, 2025
Registry last updated
Dec 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.